Fiona Hilton

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

B-J Kullberg, JD Sobel, Markus Ruhnke et al. · The Lancet · 2005 · 522 citations

Life Sciences, Microbiology, Pharmacology +15

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer

Philip E. Lammers, Magdolna Dank, Riccardo Masetti et al. · British Journal of Cancer · 2018 · 58 citations · Full text

Medicine, Oncology, Pharmacokinetics +17

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

Niels Reinmuth, Maciej Bryl, Igor Bondarenko et al. · BioDrugs · 2019 · 56 citations · Full text

Medicine, Oncology, Pharmacology +13

A randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer

Mark D. Pegram, Elizabeth Tan-Chiu, Amy Freyman et al. · Annals of Oncology · 2017 · 19 citations · Full text

Medicine, Oncology, Pharmacology +17

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

Rubi K. Li, Eriko Tokunaga, Hryhoriy Adamchuk et al. · BioDrugs · 2022 · 12 citations · Full text

Medicine, Oncology, Pharmacology +16